by Peter Ciszewski | Sep 28, 2021
Thierry Facon, MD, Professor of Hematology at Lille University Hospital in France, discusses 5-year follow-up data from the MAIA study evaluated the addition of daratumumab to the standard of care with lenalidomide and dexamethasone in multiple myeloma...
by Peter Ciszewski | Sep 27, 2021
Drug compounding is often regarded as the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. What Physicians Should Know About Compounded Drugs Julie Dohm, PhD, JD, Of Counsel at Covington &...
by Peter Ciszewski | Sep 24, 2021
The Food and Drug Administration (FDA) has approved ruxolitinib (Jakafi) to treat chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in patients 12 years and older. Chronic GVHD is a rare complication that can occur after a...
by Peter Ciszewski | Sep 23, 2021
Kylie O’Keefe, Senior Vice President, Head of Global Commercial and Corporate Strategy at PTC Therapeutics, describes early signs and symptoms of aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare, genetic disorder due to a defect...
by Peter Ciszewski | Sep 23, 2021
Michael Panzara, MD, MPH, Chief Medical Officer at Wave Life Sciences, provides an overview of the pathophysiology of Huntington disease and how that knowledge is guiding treatment development. Huntington disease is an inherited, neurodegenerative disorder that...
